SARS-CoV2 Infection: Clinical Trials

19 trials for SARS-CoV2 Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 6 unknown, 4 withdrawn, 3 terminated. 19 Phase 2, 7 Phase 3, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 219Completed 6, Unknown 6, Withdrawn 4, Terminated 3
Phase 37Completed 2, Unknown 2, Withdrawn 2, Terminated 1
Phase 13Completed 3

Follow SARS-CoV2 Infection: new trials by email Literature Review of SARS-CoV2 Infection trials Research Report on SARS-CoV2 Infection

Trials (filtered) newest first · largest first

All 19 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
NAC for Attenuation of COVID-19 Symptomatology
N-acetylcysteine, Placebo - Covid19, COVID-19 Pneumonia
Phase 2UnknownCambridge Health Alliance2002024-03-312023-08-07
Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine
PHH-1V81, Comirnaty Omicron XBB1.5 - SARS-CoV2 Infection
Phase 2 / Phase 3CompletedHipra Scientific, S.L.U9132023-11-152026-03-12
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
Fostamatinib, Placebo - COVID-19, SARS-CoV2 Infection
Phase 2 / Phase 3TerminatedNEAT ID Foundation282022-10-272025-05-02
Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea
Combination regimen: Fluoxetine, Prednisolone, Ivermectin, Combination regimen: Albendazole, Vitamin C - SARS-CoV2 Infection, COVID-19
Phase 2 / Phase 3WithdrawnOriol Mitja2022-05-012023-03-09
A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine
SCTV01C, Comirnaty - COVID-19, SARS-CoV2 Infection
Phase 2WithdrawnSinocelltech Ltd.2022-04-252024-02-09
Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19
Candesartan Cilexetil, Repagermanium, Candesartan Placebo - COVID-19, SARS-CoV2 Infection
Phase 2TerminatedUniversity of Sydney492022-01-072023-09-15
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
Famotidine, Celecoxib, Placebo - 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Phase 2TerminatedLeidos Life Sciences42021-12-292024-07-09
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
BMS-986414, BMS-986413 - SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Phase 2WithdrawnImperial College Healthcare NHS Trust2021-11-292023-04-24
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
Masitinib Mesylate, Placebo - Covid19, SARS-CoV2 Infection
Phase 2UnknownAB Science782021-11-232023-02-06
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
Basiliximab Injection, Placebo - SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection
Phase 2UnknownFort Worth Clinical Sciences Working Group3002021-10-152021-08-19
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
GX-19N, Placebo - SARS-CoV2 Infection
Phase 2 / Phase 3WithdrawnGenexine, Inc.2021-10-012022-04-12
Efficacy of Ivermectin in COVID-19
Ivermectin, Placebo - Safety, SARS-CoV2 Infection
Phase 1 / Phase 2CompletedBangkok Metropolitan Administration Medical College and Vajira Hospital722021-09-012021-12-15
Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients
Exosome-MSC Intravenous injection, Placebo Intravenous Injection, COVID-19 Standard Treatment - SARS-CoV2 Infection
Phase 2 / Phase 3UnknownDermama Bioteknologi Laboratorium602021-07-012022-02-18
COVAXIN in a Pediatric Cohort
COVAXIN - SARS-CoV2 Infection
Phase 2 / Phase 3CompletedBharat Biotech International Limited5252021-05-262022-08-18
Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2
Vaxzevria, Comirnaty - SARS-CoV2 Infection
Phase 2UnknownMedical University Innsbruck30002021-05-102021-09-10
Effect of IMMUNEPOTENT-CRP on Serum Pro-Inflammatory Cytokines in Mild to Moderate COVID-19
IMMUNEPOTENT-CRP (I-CRP), Placebo Comparator - COVID-19, SARS-CoV2 Infection
Phase 1 / Phase 2CompletedUniversidad Autonoma de Nuevo Leon802021-04-202024-11-08
Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection
Nitazoxanide and Ciclésonide, Telmisartan 20Mg Oral Tablet, Paracetamol - Covid19, Covid19 Drug Treatment
Phase 2 / Phase 3UnknownANRS, Emerging Infectious Diseases6002021-04-122023-01-31
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
Rayaldee, Placebo - COVID-19, Coronavirus
Phase 2CompletedOPKO Health, Inc.1712020-11-022024-05-28
Sildenafil in COVID-19
Sildenafil, Placebo - Covid19, SARS-COV2 Infection
Phase 1 / Phase 2CompletedUniversidad Nacional Andres Bello402020-08-192021-09-29

Narrower conditions

COVID-19 (19)  ·  Cytokine Release Syndrome (3)  ·  Coronavirus Infections (2)  ·  Leukemia (1)  ·  Lymphoma (1)  ·  Neoplasms, Plasma Cell (1)  ·  Purpura, Thrombocytopenic, Idiopathic (1)  ·  Purpura, Thrombotic Thrombocytopenic (1)

Broader conditions

Coronaviridae Infections (19)  ·  Infections (19)  ·  Lung Diseases (19)  ·  Nidovirales Infections (19)  ·  Pneumonia (19)  ·  Pneumonia, Viral (19)  ·  RNA Virus Infections (19)  ·  Respiratory Tract Diseases (19)  ·  Respiratory Tract Infections (19)  ·  Virus Diseases (19)  ·  Coronavirus Infections (17)  ·  Pathologic Processes (4)  ·  Pathological Conditions, Signs and Symptoms (4)  ·  Inflammation (3)  ·  Shock (3)

Interventions

BNT162 Vaccine (2)  ·  Ivermectin (2)  ·  Acetaminophen (1)  ·  Acetylcysteine (1)  ·  Ascorbic Acid (1)  ·  BBV152 COVID-19 vaccine (1)  ·  Basiliximab (1)  ·  Calcifediol (1)  ·  Celecoxib (1)  ·  ChAdOx1 nCoV-19 (1)  ·  Famotidine (1)  ·  Fluoxetine (1)  ·  GX-19N vaccine (1)  ·  Prednisolone (1)  ·  SCTV01C vaccine (1)

Sponsors

AB Science (1)  ·  ANRS, Emerging Infectious Diseases (1)  ·  Bangkok Metropolitan Administration Medical College and Vajira Hospital (1)  ·  Bharat Biotech International Limited (1)  ·  Cambridge Health Alliance (1)  ·  Dermama Bioteknologi Laboratorium (1)  ·  Fort Worth Clinical Sciences Working Group (1)  ·  Genexine, Inc. (1)  ·  Hipra Scientific, S.L.U (1)  ·  Imperial College Healthcare NHS Trust (1)  ·  Leidos Life Sciences (1)  ·  Medical University Innsbruck (1)  ·  NEAT ID Foundation (1)  ·  OPKO Health, Inc. (1)  ·  Oriol Mitja (1)

Countries

United States (3)  ·  India (2)  ·  South Africa (2)  ·  Spain (2)  ·  Austria (1)  ·  Brazil (1)  ·  Burkina Faso (1)  ·  Chile (1)  ·  France (1)  ·  Germany (1)  ·  Guinea (1)  ·  Indonesia (1)  ·  Italy (1)  ·  Mexico (1)  ·  Russia (1)

Top investigators

Akhtar Ashfaq, MD FACP FASN (1)  ·  Andy Peniket (1)  ·  Anton Pozniak, Prof (1)  ·  Bambang Darwono, Dr.Sp.OT (1)  ·  Brian A Roberts, MS, PMP (1)  ·  Cristina Rodriguez-Padilla, Ph.D. (1)  ·  Dorothee von Laer, MD (1)  ·  Dr Mirza Nizam Baig, MBBS,MD (1)  ·  Dr Padmavathi I V, MBBS,MD (1)  ·  Dr Prashanth Siddiah, MBBS,MD (1)  ·  Dr.Jai Prakash Narayan, MBBS,MD (1)  ·  Dr.Lokesh Kumar Tiwari, MBBS,DNB (1)  ·  Dr.V.N Tripathi, MBBS,MD (1)  ·  Dr.Vasant Khalatkar, MBBS,MD (1)  ·  Felipe Martinez, MD, MSc (1)

Results publications

PMID 34980198, PMID 35617826, PMID 35717995, PMID 36028897, PMID 36048877, PMID 36574985, PMID 39438096